Published in J Immunol on September 15, 1993
Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell (1998) 2.24
Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med (2000) 2.00
Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol (2004) 1.88
Effect of exposure to swine dust on levels of IL-8 in airway lavage fluid. Thorax (1997) 1.32
Induction of IL-8 production in human alveolar macrophages and human bronchial epithelial cells in vitro by swine dust. Thorax (1998) 1.26
Role of neutrophils in the pathogenesis of experimental vasculitis. Am J Pathol (1996) 1.23
Polyphenol-rich pomegranate fruit extract (POMx) suppresses PMACI-induced expression of pro-inflammatory cytokines by inhibiting the activation of MAP Kinases and NF-kappaB in human KU812 cells. J Inflamm (Lond) (2009) 1.13
Release of vasoactive cytokines by antibody-enhanced dengue virus infection of a human mast cell/basophil line. J Virol (2000) 1.13
Dengue virus selectively induces human mast cell chemokine production. J Virol (2002) 1.12
Interleukin (IL)-10 inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. J Clin Invest (1996) 1.10
Mast cell activation and migration to lymph nodes during induction of an immune response in mice. J Clin Invest (1998) 1.09
Dexamethasone inhibition of leucocyte adhesion to rat mesenteric postcapillary venules: role of intercellular adhesion molecule 1 and KC. Gut (1999) 1.04
Induced expression of mRNA for IL-5, IL-6, TNF-alpha, MIP-2 and IFN-gamma in immunologically activated rat peritoneal mast cells: inhibition by dexamethasone and cyclosporin A. Immunology (1995) 1.01
Gram positive bacteria induce IL-6 and IL-8 production in human alveolar macrophages and epithelial cells. Inflammation (1999) 1.01
Touch of chemokines. Front Immunol (2012) 1.00
Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology (2003) 0.97
Substance P-induced inflammatory responses in guinea-pig skin: the effect of specific NK1 receptor antagonists and the role of endogenous mediators. Br J Pharmacol (1995) 0.96
Immune cells and angiogenesis. J Cell Mol Med (2009) 0.96
Sequential histopathology at the Rhipicephalus sanguineus tick feeding site on dogs and guinea pigs. Exp Appl Acarol (1999) 0.94
Comparative cytokine gene expression: regulation and release by human mast cells. Immunology (1998) 0.89
Butrin, isobutrin, and butein from medicinal plant Butea monosperma selectively inhibit nuclear factor-kappaB in activated human mast cells: suppression of tumor necrosis factor-alpha, interleukin (IL)-6, and IL-8. J Pharmacol Exp Ther (2010) 0.88
IL-4 enhances IL-3 and IL-8 gene expression in a human leukemic mast cell line. Immunology (1995) 0.87
Borrelia burgdorferi spirochetes induce mast cell activation and cytokine release. Infect Immun (1999) 0.87
Bone marrow angiogenesis and progression in multiple myeloma. Am J Blood Res (2011) 0.87
Oral administration of herbal mixture extract inhibits 2,4-dinitrochlorobenzene-induced atopic dermatitis in BALB/c mice. Mediators Inflamm (2014) 0.86
Mast cells in melanocytic tumours. Arch Dermatol Res (1995) 0.82
Contrasting roles for RANTES and macrophage inflammatory protein-1 alpha (MIP-1 alpha) in a murine model of allergic peritonitis. Clin Exp Immunol (1999) 0.81
Adhesion of human mast cells to extracellular matrix provides a co-stimulatory signal for cytokine production. Immunology (1999) 0.80
Differential effects of the PAF receptor antagonist UK-74,505 on neutrophil and eosinophil accumulation in guinea-pig skin. Br J Pharmacol (1994) 0.77
Genomic responses during acute human anaphylaxis are characterized by upregulation of innate inflammatory gene networks. PLoS One (2014) 0.77
The strain difference in the effect of mercuric chloride on antigen-triggered serotonin release from rat mast cells is not mediated via interferon-gamma. Immunology (1996) 0.76
Medium dose ultraviolet A1 phototherapy and mRNA expression of interleukin 8, interferon γ, and chemokine receptor 4 in acute skin lesions in atopic dermatitis. Postepy Dermatol Alergol (2016) 0.75
Regulatory effects of cytokine production in atopic allergic reaction by gammi-danguieumja. Inflammation (2004) 0.75
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev (2000) 2.98
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol (1993) 2.44
Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell (1998) 2.24
Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol (2012) 1.77
Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol (2014) 1.63
Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res (2010) 1.60
Cytokine modulation of keratinocyte cytokines. J Invest Dermatol (1990) 1.59
Long-term administration of pancuronium and pipecuronium in the intensive care unit. Anesth Analg (1994) 1.56
Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol (2000) 1.55
C3a and C5a stimulate chemotaxis of human mast cells. Blood (1997) 1.55
Melanocytes as "sensory" and regulatory cells in the epidermis. J Theor Biol (1993) 1.55
Pseudoallergen-free diet in the treatment of chronic urticaria. A prospective study. Acta Derm Venereol (1995) 1.54
Mast cells. Int J Dermatol (1995) 1.52
Quantification of mitochondrial DNA in human blood cells using an automated detection system. Forensic Sci Int (2000) 1.50
Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol (1995) 1.50
Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol (2012) 1.49
Hypocomplementaemic urticarial vasculitis: successful treatment with cyclophosphamide-dexamethasone pulse therapy. Br J Dermatol (1998) 1.47
Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma. Onkologie (2004) 1.43
Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol (1999) 1.40
[Recurrent nodular panniculitis in alpha 1-antitrypsin deficiency. Successful dapsone therapy]. Hautarzt (1993) 1.39
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer (2013) 1.38
Alkaline phosphatase activity and localization during the murine hair cycle. Br J Dermatol (1994) 1.34
Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis. J Allergy Clin Immunol (2000) 1.33
Chemotherapy-induced alopecia in mice. Induction by cyclophosphamide, inhibition by cyclosporine A, and modulation by dexamethasone. Am J Pathol (1994) 1.30
Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis (1999) 1.30
International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol (2003) 1.29
Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res (2009) 1.29
Eosinophil chemotactic factor (ECF). I. Release from polymorphonuclear leukocytes by the calcium ionophore A23187. J Immunol (1976) 1.27
Shiitake dermatitis. Br J Dermatol (2003) 1.27
Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother (2000) 1.27
Involvement of hepatocyte growth factor/scatter factor and met receptor signaling in hair follicle morphogenesis and cycling. FASEB J (2000) 1.26
Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A (2001) 1.24
The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer (1999) 1.22
Eosinophil chemotactic factor (ECF). II. Release from human polymorphonuclear leukocytes during phagocytosis. J Immunol (1976) 1.22
E- and P-cadherin expression during murine hair follicle morphogenesis and cycling. Exp Dermatol (1999) 1.22
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol (1997) 1.20
A murine model for inducing and manipulating hair follicle regression (catagen): effects of dexamethasone and cyclosporin A. J Invest Dermatol (1994) 1.18
Hair follicle expression of 1,25-dihydroxyvitamin D3 receptors during the murine hair cycle. Br J Dermatol (1994) 1.18
Deficient IL-12p70 secretion by dendritic cells based on IL12B promoter genotype. Genes Immun (2004) 1.18
Biomarkers in melanoma. Ann Oncol (2009) 1.17
Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol (2004) 1.16
Drug-resistance in human melanoma. Int J Cancer (2001) 1.15
Electron microscopical evidence for a direct contact between nerve fibres and mast cells. Acta Derm Venereol (1981) 1.15
Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis (2000) 1.14
Coexisting lichen planus and subacute cutaneous lupus erythematosus. Clin Exp Dermatol (1995) 1.13
Leukotriene B4 induces in vitro fibroblast chemotaxis. J Invest Dermatol (1984) 1.13
Membrane translocation of 15-lipoxygenase in hematopoietic cells is calcium-dependent and activates the oxygenase activity of the enzyme. Blood (1998) 1.12
Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival. Br J Cancer (2002) 1.11
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer (2011) 1.10
Prevalence of cholinergic urticaria in young adults. J Am Acad Dermatol (1994) 1.08
Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours. J Pathol (1993) 1.08
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
Mast cell involvement in murine hair growth. Dev Biol (1994) 1.06
Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol (1998) 1.06
Towards defining the pathogenesis of the hairless phenotype. J Invest Dermatol (1998) 1.06
Reconstruction of large defects on the scalp and forehead as an interdisciplinary challenge: experience in the management of 39 cases. Eur J Surg Oncol (2006) 1.05
Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer (2001) 1.05
Human dendritic cells infected by Listeria monocytogenes: induction of maturation, requirements for phagolysosomal escape and antigen presentation capacity. Eur J Immunol (2000) 1.04
D-glucose-6-phosphate dehydrogenase (Entner-Doudoroff enzyme) from Pseudomonas fluorescens. Purification, properties and regulation. Eur J Biochem (1975) 1.04
Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer (2002) 1.03
Keratin 17 gene expression during the murine hair cycle. J Invest Dermatol (1997) 1.03
DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells. FEBS Lett (2001) 1.03
Dose-dependent severe cutaneous reactions to imatinib. Br J Cancer (2003) 1.03
Mast cells as initiators of immunity and host defense. Exp Dermatol (2001) 1.02
Role of p53 in UVB-induced apoptosis in human HaCaT keratinocytes. J Invest Dermatol (1997) 1.02
Phenotypic evaluation of cultured human mast and basophilic cells and of normal human skin mast cells. Arch Dermatol Res (1994) 1.02
Human epidermal cells synthesize HLA-DR alloantigens in vitro upon stimulation with gamma-interferon. J Invest Dermatol (1985) 1.01
Transforming growth factor-beta receptor type I and type II expression during murine hair follicle development and cycling. J Invest Dermatol (1997) 1.01
PO2-profiles in hippocampal slices of the guinea pig. Exp Brain Res (1982) 0.99
Autosomal dominant lamellar ichthyosis: a new skin disorder. Clin Genet (1984) 0.98
A role for p75 neurotrophin receptor in the control of apoptosis-driven hair follicle regression. FASEB J (2000) 0.98
In vitro and in vivo chemotaxis of guinea pig leukocytes toward leukotriene B4 and its w-oxidation products. Prostaglandins (1985) 0.98
Stem cell factor, a novel cutaneous growth factor for mast cells and melanocytes. Arch Dermatol Res (1994) 0.98
Ichthyosis bullosa of Siemens: a unique type of epidermolytic hyperkeratosis. J Am Acad Dermatol (1986) 0.98
The bulge is the source of cellular renewal in the sebaceous gland of mouse skin. Arch Dermatol Res (2000) 0.98
Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial. J Eur Acad Dermatol Venereol (2013) 0.97
Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 act as "epitheliotrophins" in murine skin. Lab Invest (1999) 0.97
Mast cells and vasculature in atopic dermatitis--potential stimulus of neoangiogenesis. Allergy (2005) 0.97
Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol (2000) 0.97
Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med (1995) 0.97
Management of leukocytoclastic vasculitis. J Dermatolog Treat (2005) 0.97
Demonstration of the high-affinity IgE receptor on human Langerhans cells in normal and diseased skin. Br J Dermatol (1993) 0.97
Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer. Br J Dermatol (2002) 0.97
Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int J Cancer (2000) 0.96
The polymerase chain reaction. Method and applications in dermatopathology. Am J Dermatopathol (1993) 0.96
Patterns of cell death: the significance of apoptosis for dermatology. Exp Dermatol (1993) 0.96
[Hydroxyethyl starch accumulation in the skin with special reference to hydroxyethyl starch-associated pruritus]. Dtsch Med Wochenschr (2000) 0.96